Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)

This study is currently recruiting participants.
Verified October 2013 by Massachusetts General Hospital
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Eli Lilly and Company
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Jorg Dietrich, M.D., Ph.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00916630
First received: June 5, 2009
Last updated: October 22, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)